Skip to main content

LA VIA DE LOS GLUCOCORTICOIDES EN LA DISTROFIA MUSCULAR CONGENITA RELACIONADA CON LMNA: DESCIFRANDO MECANISMOS Y PROBANDO ESTRATEGIAS TERAPEUTICAS

PID2023-147678OB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2023
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre INSTITUTO DE SALUD CARLOS III DE MADRID (ISCIII)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Docta Complutense
Publication Artículo científico (JournalArticle)

Cannabinoid CB2 receptor drives trastuzumab resistance and predicts durable anti-HER2 response

  • Seijo Vila, Marta
  • Balsinde, Sofía A.
  • Blasco Benito, Sandra
  • Tundidor, Isabel
  • Rubert Hernández, María
  • Montero Calle, Ana
  • Barderas Manchado, Rodrigo
  • Kilpatrick, Laura E.
  • Platt, Simon
  • Karsai, Noemi
  • Philps, Isabel
  • Antón Hurtado, Olga María
  • Gómez Domínguez, Déborah
  • Pérez de Castro, Ignacio
  • González Lois, Carmen
  • García Fresnadillo, Diego
  • Silvestre Egea, Gala
  • Sánchez López, Antonio J.
  • Ramírez Medina, Esther
  • Rivas Prieto, María Catalina
  • Almoguera Pérez Cejuela, Belén
  • Manso, Luis
  • Zazo, Sandra
  • López Ejeda, Noemí
  • Palomino Duque, Francisco
  • Turienzo Durán, María
  • García Martínez-Illescas, Nuria
  • Salazar Roa, María
  • Castillo Lluva, Sonia
  • Hill, Stephen J.
  • Guzmán Pastor, Manuel
  • Pérez Gómez, Eduardo
  • Sánchez García, María Cristina
Acquired or innate lack of response to standard HER2-targeted therapies remains a clinical issue in patients with HER2-positive breast cancer. Here, we investigated the role of the cannabinoid CB2 receptor (CB2R) in trastuzumab resistance. In human breast cancer samples, a decreased expression of HER2-CB2R heterodimers following neoadjuvant treatment, due to CB2R downregulation, was linked to poor long-term outcomes. Using various preclinical models, we demonstrate that CB2R drives trastuzumab resistance. Mechanistically, CB2R loss enabled cancer cells to evade antitumor IFN-γ signaling while promoting a shift from HER2-CB2R to HER2-EGFR heterodimers, thus reducing dependence on HER2 and increasing reliance on EGFR-mediated pathways. Moreover, EGFR inhibition restored trastuzumab sensitivity. In summary, we reveal an unprecedented role for CB2R as a key regulator of oncogenic and immune signaling in response to anti-HER2 therapy and its potential as a predictive biomarker of therapeutic efficacy. We also propose dual HER2/EGFR targeting and non-CB2R-selective cannabinoid therapies as potential strategies to overcome CB2R-mediated trastuzumab resistance. Together, these findings position the endocannabinoid system as a pivotal and actionable node to elucidate, anticipate, and counteract resistance to HER2-targeted therapies.